Toripalimab  (Synonyms: 特瑞普利单抗)

Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

在转染了 PD-1 质粒的 293F 细胞中，Toripalimab 与 PD-1 (EC₅₀ 21 nmol/L) 特异性结合，并抑制 PD-1 与 PD-L1 [IC₅₀ 3.0 nmol/L (≈ 0.5 μg/mL)] 和 PD-L2 (IC₅₀ 3.1 nmol/L) 的结合^[2]。
Toripalimab (0.01–10 μg/mL) 以剂量依赖性方式促进人类 T 细胞增殖^[2]。
Toripalimab 促进活化的人外周血单核细胞 (PBMC) 衍生的 T 细胞中TNF-γ 和 TNF-α 的分泌^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Toripalimab (0.3-10 mg/kg；腹腔注射；每周两次，共 6 次) 以剂量依赖性方式表现出显著的肿瘤抑制功能^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.3 kDa

1924598-82-2

液体

Colorless to light yellow

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-7396) can bind Toripalimab. The EC₅₀ for this effect is 7.504 ng/mL.

• [1]. Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.  [Content Brief]

  [2]. Keam SJ. Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578.  [Content Brief]

  [3]. Liu H, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690.  [Content Brief]